glp-1 agonists cardiovascular diseases Glucagon-like peptide 1 receptor agonists: benefits and mechanisms of action GLP-1 Agonists in Cardiovascular Diseases:

One of those dual agonists, tirzepatide (Mounjaro/Zepbound, Eli Lilly), was associated with a mean 14.7% weight loss for adults with overweight or obesity and type 2 diabetes in the SURMOUNT-2 trial compared with a 3.2% weight loss with placebo

By targeting these chemicals in the brain, Contrave helps to promote weight loss

Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects

[DOI] [PubMed] [Google Scholar] 71.Lee H, Chung HJ, Pawar A, Patorno E, Kim DH

In fact, the inspiration for this article comes from both seeing remarkable anecdotal accounts from people on these drugs, but also the recent trials of Tirzepatide and Taltz showing actual benefit

Stekovic, S